Aier Eye Hospital, once the darling of China’s private healthcare sector, is facing a moment of reckoning. On May 20, the ophthalmology giant announced it would pay 524 million yuan ($72.5 million) in back taxes and late fees following a self-inspection. This massive outlay, representing nearly half of the company’s first-quarter profits for 2026, sent shockwaves through the market, wiping out 3.8 billion yuan in market capitalization in a single day.
The timing of the tax bill is particularly sensitive as Aier prepares for a secondary listing on the Hong Kong Stock Exchange. Just a month prior, the board approved the IPO plan, marking a sharp reversal from Chairman Chen Bang’s previous stance that the company had no need for Hong Kong capital. This sudden pivot suggests an urgent need to bolster the balance sheet and provide a platform for international expansion as domestic growth engines begin to sputter.
For the first time since its 2009 listing, Aier reported a decline in annual net profit for 2025, falling 8.88% year-on-year. This slump highlights the exhaustion of the company’s aggressive acquisition-led growth model, which has left it with a staggering 9.49 billion yuan in net goodwill. As these acquired hospitals struggle to meet performance targets, the threat of massive write-downs looms over the company’s valuation like a financial guillotine.
Beyond the balance sheet, Aier’s operational ethics are under fire. Regulators and investigative reports have flagged a suspicious 'charity loop' where company-linked foundations fund surgeries at Aier hospitals, effectively laundering public insurance funds into private revenue. This practice, combined with a string of medical insurance fraud penalties across its vast network of subsidiaries, paints a picture of a corporation that prioritized rapid scaling over internal compliance and governance.